Kura Oncology (KURA) investor relations material

Executive summary

• KOMZIFTI generated $13.9M in Q3 net product revenue, up 53% QoQ, with new patient starts up 30% and a majority share of menin inhibitor starts in R/R NPM1-mutated AML.

• Ziftomenib development spans frontline and combination AML settings; darlifarnib is advancing toward a registrational study in HRAS-mutant salivary gland cancer and combination studies.

Financial highlights

• Q3 revenue was $22.8M versus $20.8M a year earlier, including $13.9M in KOMZIFTI sales and $8.9M in collaboration revenue versus $20.8M.

• Q3 R&D expense was $66.9M versus $67.9M; SG&A was $30.2M versus $32.8M; net loss was $70.2M versus $74.1M.

• Nine-month revenue was $62.0M versus $50.1M; net loss was $211.9M versus $197.7M, including $28.8M in KOMZIFTI product revenue and $33.2M in collaboration revenue.

• Cash, cash equivalents and short-term investments totaled $492.1M at September 30, 2026, versus $667.2M at December 31, 2025.

Outlook and guidance

• Collaboration revenue guidance is $40M–$45M for 2026 and $90M–$110M for each of 2027 and 2028; it reflects non-cash revenue recognition, not cash receipt timing.

• Cash and anticipated $180M in Kyowa Kirin milestones, alongside conditional Oberland funding, are expected to support operations beyond initial KOMET-017 topline results anticipated in 2028.

• KOMET-017 enrollment is progressing as planned; initial topline results from the intensive chemotherapy trial, including its MRD-negative CR endpoint, are anticipated in 2028.

• A ~40-patient darlifarnib registrational study in HRAS-mutant salivary gland cancer is targeted to start in H1 2027 following a planned Q4 2026 IND; FDA alignment supports a single-arm monotherapy design.

• FIT-001 RCC enrollment is expected to finish in H1 2027, with initial data in H2; a darlifarnib-daraxonrasib PDAC study is planned for H1 2027, with preliminary data targeted for H2.